Events
| 2009-06-12 |
Dr. John Dong to present at 2009 Japan Society for Gene Therapy meeting, Osaka, Japan |
| Osaka University Convention Center, July 9-11, 2009 |
| International Symposium of Gene Therapy - "Cutting Edge of Cancer Gene Therapy" A NOVEL ONCOLYTIC VECTOR THERAPY APPROACH THAT COMBINES PROSTATE-SPECIFIC VECTOR REPLICATION WITH VACCINE ANTIGEN PRESENTATION Japan Society for Gene Therapy |
| About GenPhar, Inc. GenPhar, Inc. is a biopharmaceutical company dedicated to becoming a leader in developing and producing prophylactic and therapeutic vaccines to protect against the world’s most dangerous diseases. To reach its goals, GenPhar will leverage the advantage of its proven safe and effective ProVax and TheraVax vaccine platforms -- unique technology capable of producing multiple vaccine products. GenPhar's products are divided into two main areas: vaccines for biodefense and vaccines for chronic infectious diseases (including HIV, hepatitis B and hepatitis C). These products will have a large scale socio-economic impact and transformative effect on current research and treatments. GenPhar was founded in 1999 and is headquartered in Mount Pleasant, South Carolina. To learn more about GenPhar and its vaccine programs, please contact us. |


print this page
site map